OKLAHOMA CITY, OK--(Marketwired - February 18, 2014) -
Cytovance Biologics, Inc., a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces that they have entered into a development and manufacturing agreement with Pamlico Biopharma, Inc., an Oklahoma City-based clinical stage biopharmaceutical company.
Pamlico Biopharma has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections. Pamlico has contracted Cytovance Biologics as its CMO to develop a production cell line from the protein's amino acid sequence for GMP manufacture of phase I clinical material.
"With this agreement, Pamlico Biopharma has reached a milestone in the development of a therapeutic antibody product for the treatment of Streptoccocus pneumoniae, a leading cause of Severe Community Acquired Pneumonia (SCAP) which can lead to hospitalization and death," said Clayton Duncan, CEO of Pamlico Biopharma, Inc.
"Cytovance's state-of-the-art facilities and experienced staff are prepared to deliver the highest quality of development and manufacturing services for Pamlico Biopharma," said Darren Head, President and Chief Executive Officer of Cytovance Biologics. "We are delighted to be working with such an innovative company that uses technologies from the Oklahoma Medical Research Foundation and advance the treatment of Streptococcus pneumoniae infections that are associated with over 50,000 deaths annually."
About Pamlico Biopharma, Inc.
Pamlico Biopharma, Inc., an Accele Biopharma Inc. client company, was founded around human monoclonal antibody therapeutics and technologies from the Oklahoma Medical Research Foundation and from Emory University. PAMLICO focuses on human monoclonal antibody therapeutics for human pathogens, cancer and autoimmune diseases. The lead project will address SCAP caused by S pneumoniae. Pneumococcal pneumonia remains a major cause of morbidity and mortality worldwide.
About Accele Biopharma Inc.
Accele Biopharma ("Accele") and Accele Venture Partners, a related special purpose venture fund, were formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking, early-stage life science technologies that have the potential to dramatically improve human healthcare, have strong commercial promise and have the potential for generating early proof of concept data. To achieve this goal Accele has assembled an experienced management team, a group of sophisticated investors, a nationally recognized advisory board, research facilities and the broad scientific expertise necessary to evaluate and manage such opportunities.
Accele currently has four companies under management: Otologic Pharmaceutics, Inc. focusing on a clinical stage treatment for hearing loss; Pamlico Biopharma, Inc., focusing on human monoclonal antibody therapeutics for human pathogens, cancer and autoimmune diseases, with a lead project addressing pneumonia caused by S pneumoniae; Synereca Pharmaceuticals, Inc., developing novel drugs that inhibit the bacterial enzyme RecA to address the growing problem of antibiotic resistance; and Jortan Pharmaceuticals, Inc., pursuing the discovery and development of BACE-2 (Memapsin 1) inhibitors as a novel approach to the treatment of type 2 diabetes.
For further information regarding Accele Biopharma Inc. and Pamlico Biopharma, Inc., see www.accelebio.com.
About Cytovance Biologics, Inc.
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Learn more about Cytovance Biologics at www.cytovance.com.